Uthealthjoins trial of arthritis drug’s effect on COVID-19-induced cytokine storm
正在研究一种药物，因为它在治疗休斯顿大学健康科学中心的研究人员麦戈文医学院（McGovern Medical School）的COVID-19引起的COVID-19诱导的肺炎患者中的有效性（beplay苹果手机能用吗Uthealth). The clinical trial is enrolling patients at Harris Health System’s Lyndon B. Johnson Hospital.
第三阶段，多站点，随机，双盲，安慰剂对照研究正在评估药物Canakinumab的有效性，Canakinumab是一种批准用于治疗少年类风湿关节炎的白介素-1（IL-1）阻滞剂，以防止细胞因子释放综合征（CRS）在199例肺炎患者中。
Often referred to as a cytokine storm, CRS is a life-threatening immune reaction caused by the body releasing too many cytokines into the blood at once. Cytokines include a broad category of proteins secreted by the body. IL-1 serves as the first-line defense for the immune system, alerting other proteins to respond if a virus or bacteria are present.
canakinumab阻止了IL-1蛋白的产生，这可能会防止在199例患者中可能致命的免疫系统反应过度反应。beplay苹果手机能用吗has linked a number of COVID-19 deaths to CRS due to damage caused to several major organs.
Covid-19-Pandemic提醒Uthealth的研究人员艾滋病beplay苹果手机能用吗毒大流行的早期，当时混乱和恐惧影响了许多社区，几乎没有治疗选择。
Roberto C. Arduino，医学博士，该研究的主要研究员和传染病教授和McGovern Medical School在Uthealth说，这是艾滋病毒研究界利用成员的专业知识来寻求冠状病毒治疗的时候。beplay苹果手机能用吗Arduino的研究beplay苹果手机能用吗背景包括研究新的抗逆转录病毒药物，治疗策略，免疫激活和炎症，以寻求HIV治疗。
“The research community truly feels compelled to do something in the search for a viable treatment for COVID-19, and I feel I owe it to my community to offer my expertise,” said Arduino, who has led HIV clinical research for 22 years.
Researchers are investigating if canakinumab combined with standard-of-care treatment can increase the chances of survival without ever requiring invasive mechanical ventilation in patients with COVID-19-induced pneumonia. Over a two-hour period, patients who are enrolled will receive either a 450 mg, 600 mg, or a 750 mg IV dose of canakinumab based on their body weight; or placebo. All participants will be monitored for up to 29 days, or until they are discharged from the hospital. A follow-up will occur at 127 days.
Novartis Pharmaceuticals and the National Institutes of Health AIDS Clinical Trials Network are sponsoring this clinical trial. For more information, visitClinicaltrials.gov。